## UNITED STATES INTERNATIONAL TRADE COMMISSION Washington, DC 20436

# MEMORANDUM ON PROPOSED TARIFF LEGISLATION of the 109<sup>th</sup> Congress <sup>1</sup>

[Date approved: November 2, 2005]<sup>2</sup>

Bill No. and sponsor: H.R. 2079 (Mr. Kevin Brady of Texas)							
Proponent name, location: Schering-Plough Corp., Kenilworth, NJ							
Other bills on product (109th Congress only): None.							
Nature of bill: Extension of temporary duty suspension through 12/31/2008.							
Retroactive effect: None.							
$Suggested\ article\ description (s)\ for\ enactment\ (including\ appropriate\ HTS\ subheading (s)):$							
2-Azetidinone, 1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)-, (3R,4S)- (Ezetimibe) (CAS No. 163222–33–1) (provided for in subheading 2933.79.08)							
Check one: X Same as that in bill as introduced.  Different from that in bill as introduced (see Technical comments section).							
Product information, including uses/applications and source(s) of imports:							

Ezetimibe is a white, crystalline powder that is soluble in ethanol, methanol, and acetone, but only sparingly soluble in water. It is a complex multi-ring aromatic compound containing carbon, hydrogen, oxygen, fluorine, nitrogen, and sulfur. The patented product is the active ingredient in the prescription drug, Zetia®, that inhibits the absorption of cholesterol from the intestine and is used to treat primary hypercholesterolemia. This drug is a non-statin cholesterol absorption inhibitor designed to reduce LDL (bad cholesterol), slightly decrease triglycerides, and slightly increase HDL (good cholesterol). Ezetimibe is imported from Singapore.

<sup>&</sup>lt;sup>1</sup> Industry analyst preparing report: Ray Cantrell (202-205-3362); Tariff Affairs contact: David Michels (202-205-3440).

<sup>&</sup>lt;sup>2</sup> Access to an electronic copy of this memorandum is available at <a href="http://usitc.gov/tata/hts/other/rel\_doc/bill\_reports/index.htm">http://usitc.gov/tata/hts/other/rel\_doc/bill\_reports/index.htm</a>

#### **Estimated effect on customs revenue:**

HTS subheading: <u>2933.79.08</u>								
	2005	2006	2007	2008	2009			
Col. 1-General rate of duty	6.5%	6.5%	6.5%	6.5%	6.5%			
Estimated value <i>dutiable</i> imports	\$2,000,000	\$2,000,000	\$2,000,000	\$2,000,000	\$2,000,000			
Customs revenue loss <u>1</u> /	\$130,000	\$130,000	\$130,000	\$130,000	\$130,000			

<sup>1/</sup> Revenue loss shown for 2005 and 2006 results from a current suspension of duties per heading 9902.01.64.

Source of estimated dutiable import data: Proponent estimates based on continuation of the FTZ.

#### Contacts with domestic firms/organizations (including the proponent):

Name of firm/organization	Date contacted	US production of same or competitive product claimed?	Submission attached?	Opposition noted?
		(Yes/No)		
Schering-Plough Corporation (Proponent) Mr. Scott McCandless, 202-414-4460 Mr. Tad Perlman, 973-822-7286	9/01/2005	No	No	No
Bayer Corporation Ms. Karen L. Niedermeyer, 412-777-2058	8/31/2005	No	No	No
Brystol-Myers Squibb Company Mr. Ron Miller, 609-897-3276	9/07/2005	No	No	No
Pfizer, Incorporated (Govt. Relations) Mr. Michael Boyd, 202-783-7070	9/07/2005	No	No	No

**Technical comments:**<sup>3</sup> None.

The Commission may express an opinion on the HTS classification of a product to facilitate consideration of the bill. However, by law, only the U.S. Customs Service is authorized to issue a binding ruling on this matter. The Commission believes that the U.S. Customs Service should be consulted prior to enactment of the bill.

## H. R. 2079

To extend the temporary duty suspension on Ezetimibe.

#### IN THE HOUSE OF REPRESENTATIVES

May 4, 2005

Mr. Brady of Texas introduced the following bill; which was referred to the Committee on Ways and Means

### A BILL

To extend the temporary duty suspension on Ezetimibe.

- 1 Be it enacted by the Senate and House of Representa-
- 2 tives of the United States of America in Congress assembled,
- 3 **SECTION 1. EZETIMIBE.**
- 4 (a) In General.—Heading 9902.01.64 of the Har-
- 5 monized Tariff Schedule of the United States (relating to
- 6 2-Azetidinone, 1-(4-fluorophenyl)-3-[(3S)-3-(4-
- 7 fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)-,
- 8 (3R,4S)-(Ezetimibe)) is amended by striking "12/31/
- 9 2006" and inserting "12/31/2008".
- 10 (b) Effective Date.—The amendment made by
- 11 subsection (a) applies to goods entered, or withdrawn from

- 1 warehouse for consumption, on or after the 15th day after
- 2 the date of the enactment of this Act.

 $\bigcirc$